Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: J Neurochem. 2006 Apr 5;97(5):1506–1518. doi: 10.1111/j.1471-4159.2006.03859.x

Table 2.

Functional potencies and relative efficacies for activation of MOR42-1 and MOR42-3.

Receptor Compound EC50 (µM) nH Relative Efficacy
Decanedioic acid 6.5 ± 1.7 1.2 ± 0.3 0.93 ± 0.06
MOR42-1 Undecanedioic acid 63 ± 31††† 0.7 ± 0.2 2.82 ± 0.36†††
Dodecanedioic acid 36 ± 16††† 0.9 ± 0.3 1.13 ± 0.13
Octanedioic acid 146 ± 28*** 0.8 ± 0.2 1.07 ± 0.11
MOR42-3 Nonanedioic acid 5.9 ± 0.9 0.9 ± 0.2 0.95 ± 0.05
Decanedioic acid 47 ± 11*** 0.8 ± 0.2 1.22 ± 0.10**

EC50 and Hill coefficient (nH) values were derived by fitting the data in Figure 8 to a Hill equation (see Experimental Procedures). Relative efficacies are the maximum values derived from fitting the data and are expressed as a ratio to the maximal responses to decanedioic acid (for MOR42-1) or nonanedioic acid (for MOR42-3). Values are the mean ± SEM derived from dose-response data from 3–7 separate oocytes. Significant differences from nonanedioic acid:

***

p<0.001,

**

p<0.01. Significant differences from decanedioic acid:

†††

p<0.001.